

# Hepatitis Delta Infection Epidemiology and Screening

Jose Debes, MD, PhD Associate Professor of Medicine Division of Infectious Diseases and International Medicine University of Minnesota

Last Updated: May 5, 2023

HEPATITIS B ONLINE www.hepatitisB.uw.edu



### None



## Hepatitis Delta (HDV)

General aspects of HDV

- Overall epidemiology of HDV
  - Risk factors
  - Epidemiology in the United States
- Screening for HDV



## **HDV General Features**

- Small RNA virus
- Requires Hepatitis B presence for infection
  - Relies on HBsAg for replication
  - Shares same hepatocyte receptor with HBV
- Two distinct transmission pathways
  - Co-infection (simultaneous HBV-HDV)
  - Super-infection (HBV then HDV)

- Can progress to cirrhosis within 2 years
  - **10-15%**
- >3-fold increase in HCC risk
  - Compared to HBV alone



Urban et al, Gut 2021

## Epidemiology

Multiple studies worldwide (numbering >2000)

- Different methodology
- Specific populations
- Different testing approach
- Estimates of HDV+ individuals in HBV+
  - **4-16%**
- Historically related to populations in West Africa and Eastern Europe





- Intravenous drug use
- HIV co-infection
- Hepatitis C co-infection
- Hemodialysis
- High risk sexual behavior



Chen et al, Gut 2019; Stockdale et al, J Hepatol 2020

### **Prevalence of Hepatitis Delta**

#### Identified 2104 studies

#### Focused on 282 studies

~122,000 persons with HBsAg+ from 6 WHO regions


General population & Hepatology clinics

#### **Prevalence of HDV**

- General population: 0.16%
- ➤ HBsAg+: <u>4.5%</u>
  - 3% Europe
  - 6% Africa
  - 6% Americas
  - 3.5% South East Asia
- Hepatology clinics: <u>16%</u>



### Prevalence of Hepatitis Delta



Prevalence of anti-HDV among HBsAg positive people in the general population

• 36%

Rep. Moldova15%

• 22%

**Togo** • 18%

Mauritania • 19%



Stockdale et al, J Hepatol 2020

Group	Odds ratio (95% CI)		
People who inject drugs 33 samples (I² = 86.7%, τ² = 1.16)	$\diamond$	19.00 (12.26, 29.45)	
Commercial sex workers 5 samples (I² = 91.5%, r² = 1.19)		18.70 (6.70, 52.17)	
Men who have sex with men 2 samples ( $I^2 = 0.0\%$ , $\tau^2 = 0.0$ )		- 16.00 (3.94, 64.92)	
Haemodialysis recipients 11 samples (I² = 21.0%, τ² = 0.49)	$\sim$	3.42 (1.38, 8.48)	
HIV, excluding generalised epidemics 18 samples (Ι² = 74.4%, τ² = 0.56)	$\diamond$	6.57 (4.08, 10.59)	
Hepatitis C virus infection 17 samples (l² = 90.7%, τ² = 1.21)	$\diamond$	10.02 (5.49, 18.26)	
Cirrhosis 29 samples (Ι² = 77.2%, τ² = 0.85)	$\diamond$	6.68 (4.37, 10.20)	
Hepatocellular carcinoma 20 samples (I² = 38.4%, τ² = 0.26)	$\diamond$	4.80 (3.18, 7.26)	
			_
Greater odds of anti-HDV relative to control populations			;

Odds ratio

## Epidemiology of Hepatitis Delta in US

- > 3-7% of HBV+
- More common in HCV, HIV, IVDU
- Genotype 1
- > Mainly among immigrant populations



## How to screen and why to screen

# How to screen

HDV antibody

# > Why to screen

- Potential treatment
- Closer follow up
  - Complications
  - HCC
- Modification of lifestyle
- Evaluation of close contacts



## Screening Recommendation from Societies

## EASL: Everyone who is HBsAg+

## >APASL: Everyone who is HBsAg+

## >AASLD: Those with HBsAg+ at high risk (2018)

- Highly endemic areas
- IVDU
- MSM
- Multiple sexual partners
- HIV, HCV
- Elevated LFTs in the setting of low HBV DNA





## General expert consensus:

<u>Who:</u> Everyone infected with HBV (HBsAg+)

How: HDV antibody



### How often to screen


- If no risk factors
  - One time

If risk factors are present (intravenous drug use, etc)

Consider once a year screening for HDV



### **Reflex Testing for Hepatitis Delta**





Palom et al, J Hepatol Rep 2022



- HDV only occurs in HBV+ individuals
  - Every HBV+ individual is at risk for HDV
- Higher risk of HDV
  - HIV, HCV, IVDU, HD, CSW
- Certain countries in Africa and Asia have higher prevalence
  - Insufficient knowledge of the overall prevalence
- Most guidelines recommend to screen every HBV+ individual for HDV
  HDV Ab





**Hepatitis B Online** is funded by a cooperative agreement from the Centers for Disease Control and Prevention (CDC-RFA-PS21-2105). This project is led by the University of Washington Infectious Diseases Education and Assessment (IDEA) Program.







The content in this presentation is that of the author(s) and does not necessarily represent the official position of the Centers for Disease Control and Prevention.